162 related articles for article (PubMed ID: 11305602)
1. A moderate interaction of maltosyl-alpha-cyclodextrin with Caco-2 cells in comparison with the parent cyclodextrin.
Ono N; Arima H; Hirayama F; Uekama K
Biol Pharm Bull; 2001 Apr; 24(4):395-402. PubMed ID: 11305602
[TBL] [Abstract][Full Text] [Related]
2. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.
Arima H; Yunomae K; Hirayama F; Uekama K
J Pharmacol Exp Ther; 2001 May; 297(2):547-55. PubMed ID: 11303042
[TBL] [Abstract][Full Text] [Related]
3. Release characteristics of endogenous constituents by exposure of small intestine to modified beta-cyclodextrins.
Tanino T; Ogiso T; Iwaki M; Yamaguchi T; Kakehi K
Biol Pharm Bull; 1999 Oct; 22(10):1099-105. PubMed ID: 10549863
[TBL] [Abstract][Full Text] [Related]
4. Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-beta-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers.
Arima H; Yunomae K; Morikawa T; Hirayama F; Uekama K
Pharm Res; 2004 Apr; 21(4):625-34. PubMed ID: 15139519
[TBL] [Abstract][Full Text] [Related]
5. Involvement of cholesterol in the inhibitory effect of dimethyl-beta-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells.
Yunomae K; Arima H; Hirayama F; Uekama K
FEBS Lett; 2003 Feb; 536(1-3):225-31. PubMed ID: 12586368
[TBL] [Abstract][Full Text] [Related]
6. 6-O-alpha-(4-O-alpha-D-glucuronyl)-D-glucosyl-beta-cyclodextrin: solubilizing ability and some cellular effects.
Tavornvipas S; Hirayama F; Arima H; Uekama K; Ishiguro T; Oka M; Hamayasu K; Hashimoto H
Int J Pharm; 2002 Dec; 249(1-2):199-209. PubMed ID: 12433448
[TBL] [Abstract][Full Text] [Related]
7. Protection afforded by maltosyl-beta-cyclodextrin against alpha-chymotrypsin-catalyzed hydrolysis of a luteinizing hormone-releasing hormone agonist, buserelin acetate.
Matsubara K; Ando Y; Irie T; Uekama K
Pharm Res; 1997 Oct; 14(10):1401-5. PubMed ID: 9358553
[TBL] [Abstract][Full Text] [Related]
8. Stabilizing and solubilizing effects of sulfobutyl ether beta-cyclodextrin on prostaglandin E1 analogue.
Uekama K; Hieda Y; Hirayama F; Arima H; Sudoh M; Yagi A; Terashima H
Pharm Res; 2001 Nov; 18(11):1578-85. PubMed ID: 11758766
[TBL] [Abstract][Full Text] [Related]
9. Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-beta-cyclodextrin, not 2,6-di-O-methyl-alpha-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells.
Motoyama K; Kameyama K; Onodera R; Araki N; Hirayama F; Uekama K; Arima H
Eur J Pharm Sci; 2009 Oct; 38(3):249-61. PubMed ID: 19664706
[TBL] [Abstract][Full Text] [Related]
10. Comparative study on inclusion complexation of maltosyl-beta-cyclodextrin, heptakis(2,6-di-O-methyl)-beta-cyclodextrin and beta-cyclodextrin with fucosterol in aqueous and solid state.
Acartürk F; Imai T; Saito H; Ishikawa M; Otagiri M
J Pharm Pharmacol; 1993 Dec; 45(12):1028-32. PubMed ID: 7908969
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of sulfobutyl ether beta-cyclodextrin on DY-9760e-induced cellular damage: In vitro and in vivo studies.
Nagase Y; Arima H; Wada K; Sugawara T; Satoh H; Hirayama F; Uekama K
J Pharm Sci; 2003 Dec; 92(12):2466-74. PubMed ID: 14603492
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of sulfate and sulfobutyl ether of beta-cyclodextrin on erythrocyte membranes in vitro.
Shiotani K; Uehata K; Irie T; Uekama K; Thompson DO; Stella VJ
Pharm Res; 1995 Jan; 12(1):78-84. PubMed ID: 7724491
[TBL] [Abstract][Full Text] [Related]
13. Acid-catalyzed hydrolysis of maltosyl-beta-cyclodextrin.
Hirayama F; Yamamoto M; Uekama K
J Pharm Sci; 1992 Sep; 81(9):913-6. PubMed ID: 1432639
[TBL] [Abstract][Full Text] [Related]
14. Varying effects of cyclodextrin derivatives on aggregation and thermal behavior of insulin in aqueous solution.
Tokihiro K; Irie T; Uekama K
Chem Pharm Bull (Tokyo); 1997 Mar; 45(3):525-31. PubMed ID: 9085557
[TBL] [Abstract][Full Text] [Related]
15. Common solubilizers to estimate the Caco-2 transport of poorly water-soluble drugs.
Takahashi Y; Kondo H; Yasuda T; Watanabe T; Kobayashi S; Yokohama S
Int J Pharm; 2002 Oct; 246(1-2):85-94. PubMed ID: 12270611
[TBL] [Abstract][Full Text] [Related]
16. Effect of sugar-modified beta-cyclodextrins on dissolution and absorption characteristics of phenytoin.
Tanino T; Ogiso T; Iwaki M
Biol Pharm Bull; 1999 Mar; 22(3):298-304. PubMed ID: 10220288
[TBL] [Abstract][Full Text] [Related]
17. Sugar-appended polyamidoamine dendrimer conjugates with cyclodextrins as cell-specific non-viral vectors.
Arima H; Motoyama K; Higashi T
Adv Drug Deliv Rev; 2013 Aug; 65(9):1204-14. PubMed ID: 23602906
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats.
Arima H; Yunomae K; Miyake K; Irie T; Hirayama F; Uekama K
J Pharm Sci; 2001 Jun; 90(6):690-701. PubMed ID: 11357172
[TBL] [Abstract][Full Text] [Related]
19. Some pharmaceutical properties of 3-hydroxypropyl- and 2,3-dihydroxypropyl-beta-cyclodextrins and their solubilizing and stabilizing abilities.
Yoshida A; Yamamoto M; Irie T; Hirayama F; Uekama K
Chem Pharm Bull (Tokyo); 1989 Apr; 37(4):1059-63. PubMed ID: 2766408
[TBL] [Abstract][Full Text] [Related]
20. Effect of cyclodextrins on biological membrane. II. Mechanism of enhancement on the intestinal absorption of non-absorbable drug by cyclodextrins.
Nakanishi K; Nadai T; Masada M; Miyajima K
Chem Pharm Bull (Tokyo); 1992 May; 40(5):1252-6. PubMed ID: 1394642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
